Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF JANUARY 12, 2022 SAM #7347
AWARD

Q -- High Throughput SARS-CoV-2 Binding Antibody Immunoassay for Testing of Clinical Samples and Variant Assessment

Notice Date
1/10/2022 5:29:03 AM
 
Notice Type
Award Notice
 
NAICS
621511 — Medical Laboratories
 
Contracting Office
BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
 
ZIP Code
20515
 
Solicitation Number
75A50122R00007
 
Archive Date
02/09/2022
 
Point of Contact
Jeffrey Schmidt, Phone: 2022050260
 
E-Mail Address
jeffrey.schmidt2@hhs.gov
(jeffrey.schmidt2@hhs.gov)
 
Award Number
75A50122C00013
 
Award Date
01/04/2022
 
Awardee
Nexelis Laboratories Canada Inc PQ H7V 3S8 CAN
 
Award Amount
14725590.10
 
Description
""High Throughput SARS-CoV-2 Binding Antibody Immunoassay for Testing of Clinical Samples and Variant Assessment"" The USG has a need for laboratory assay capacity sites for analysis of serum samples collected from subjects enrolled in COVID-19 vaccine clinical trials to provide serologic data to support the establishment of a correlate of protection to help facilitate expanded use of approved COVID-19 vaccines and accelerated approvals of additional vaccines.� Serum samples are tested to ascertain the ability of the vaccine to induce an immune response. The SARS-CoV-2 spike protein (S), which mediates binding to host cells, is highly immunogenic with the receptor-binding domain (RBD) being the target of many neutralizing antibodies. Serological analyses of COVID-19 vaccine trial specimens must be performed using the high throughput multiplex MSD-ECL immunoassay because it allows for simultaneous measurement of multiple SARS-CoV-2 proteins in the same well. The objectives of this contract are: (1) test the clinical trial samples of COVID-19 vaccines using the validated MSD-ECL immunoassay for COVID-19 in compliance with Good Clinical Laboratory Practice (GCLP); (2) develop and validate assays for SARS-CoV-2 emerging variants by the Contractor; and (3) test serum samples from human subjects enrolled in clinical trials of COVID-19 vaccines using the variant assay in compliance with GCLP.
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/e7c5a09e08564df5a8fed58bc6df5ed5/view)
 
Place of Performance
Address: Seattle, WA, USA
Country: USA
 
Record
SN06212696-F 20220112/220110230055 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.